Glenmark Pharmaceuticals has completed the pre-clinical evaluation for its novel bi-specific antibody GBR 1302 and filed the phase I trial application for the same with German regulatory authorities.
Glenmark Pharmaceuticals SA, a wholly-owned subsidiary of the company, has submitted a clinical trial application for GBR 1302 to the Paul-Ehrlich Institute in Germany, Glenmark Pharmaceuticals said in a statement.
Glenmark Pharmaceuticals SA, a wholly-owned subsidiary of the company, has submitted a clinical trial application for GBR 1302 to the Paul-Ehrlich Institute in Germany, Glenmark Pharmaceuticals said in a statement.
GBR 1302 has the potential to be used in the treatment of a broad array of cancers, including breast cancer, and the company expects to obtain approval for the initiation of clinical studies during this financial year.
Read more at:
http://economictimes.indiatimes.com/articleshow/48972234.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Tags:
News